June 10- EOD

It was a mixed bag today for biotechs with some very strong performers (TSRX and ACAD to name a few) as well as some laggards (many of the oncology companies). In general, however, it seemed like biotechs tended to be relative underperformers to the broader market. 1. Iclusig sales continued their decline from last week […]

June 7- EOD

[This was meant to be posted Friday afternoon but did not seem to go through, so you get a bonus EOD of today] I do not think there is not much out there to add from today. I will touch on a couple of themes but it was generally a bounce back day for the […]

June 6- EOD

Perhaps we had a turnaround Thursday but could of course all be crushed by a bad jobs report (or perhaps a good jobs report- you never know in this market). 1. There is some additional CELG news that has not been getting a lot of attention. As way of background, CELG 2017 guidance has about […]

June 5- EOD

Rough day in the market today and biotechs were clearly not immune. Aside from the general downtrend there were some stock specific stories. 1. There was some strategic restructuring at AVEO. This is too be expected and should cut down on the cash burn as investors wait to see if tivozanib will ever get to […]

June 4- EOD

Quite day, more or less. Some interesting ASCO news with some larger pin action. Other than that I did not see anything of particular interest. Bios were generally weak and perhaps this is the start of the long awaited biotech correction but we have had many false starts before. What is different this time is […]

June 3- EOD

Happy mid-ASCO (although most of the data is already presented). Some interesting ASCO and, surprisingly, non-ASCO stories. 1. I added to my SGEN position today (at $33.67). It has been under pressure recently and I’ve been looking to add over the summer in anticipation of HL data at ASH. I am intimately aware of the […]

May 31- EOD

Again, I feel like today was another quite before the storm day. There was some interesting news but really nothing dramatic happening. 1. Jon Najarian pumped CLSN last night as an ASCO play, which is horribly odd given that CLSN will not be at ASCO and thermodox is a complete dud of a drug. I […]

May 30- EOD

A bit of a quite day today in the markets. There is some biotech news but it seems to be the calm before the storm of ASCO, or as I heard someone note- the fire hose of data. 1. At the ELN annual meeting someone asked them about the possibility of purchasing AMRN and they […]

May 29- EOD

It seemed like a nice selloff in biotech today. There were the occasional winners (INFI) but for the most part it was a sea of red today. The summer months can be difficult times for biotechs but they have been quite resilient and these sell-offs have ended up being good buying opportunities. 1. I want […]

May 28- Mid Day

This is mid-day instead of the end of the day because I will be out of the office for the rest of the afternoon. This is a little shorter than it should be given the news and moves today but I should have time to add more to this tomorrow. 1. Looks like I have […]

May 24 – End Of Day Biotech Wrap-up

Really another slow day entering into the long weekend. From my perspective, there were really only two really interesting moves. 1. AVEO was a bit of a shocker. AVEO disclosed in a filing that Astellas will no longer fund tivozanib in RCC and would not seek approval in the EU. There are still some other […]

May 23 – End Of Day Biotech Wrap-up

Today was another macro day in that the macro environment had a lot more to do with price movements than fundamentals. That being said, bios seemed to be strong in the morning despite the sell-off and move higher when the market reversed. There was not really a lot of new news today but, as always, […]

May 22 – End Of Day Biotech Wrap-up

While the market got some intraday whipsaw action, it seemed generally good and biotechs did well- early. We had a late day sell-off with biotechs seeming to do better than the market in general. 1. It seems like just yesterday I was positive but cautious on ARIA because it was still making lower high and […]

May 21 – End Of Day Biotech Wrap-up

Perhaps it is the start of the summer season but the market seems to have been quite the past couple of days or perhaps I am simply looking at the wrong parts of the market. 1. There were a number of EHA abstracts released today for PCYC and perhaps one of the most important was […]

May 20th – End Of Day Biotech Wrap-up

Outside of a not completely unexpected merger, it was a relatively quite start to the week. As has been par for the course, ASCO oncology stocks tended to be weak but not in a significant manner. Perhaps we are having the quite before the storm. 1. PPHM announced its agreement with the FDA on a […]